Compare · ANGO vs MDLN
ANGO vs MDLN
Side-by-side comparison of AngioDynamics Inc. (ANGO) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.04B, about 69.2x ANGO ($651.0M).
- Over the past year, ANGO is up 60.9% and MDLN is down 15.3% - ANGO leads by 76.2 points.
- MDLN has hit the wire 12 times in the past 4 weeks while ANGO has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- Medline Inc.
- Price
- $15.57-1.21%
- $34.52+0.79%
- Market cap
- $651.0M
- $45.04B
- 1M return
- +14.65%
- -10.99%
- 1Y return
- +60.93%
- -15.29%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2025
- News (4w)
- 0
- 12
- Recent ratings
- 8
- 25
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Latest ANGO
- SVP Quality and Regulatory Nighan Warren Jr sold $344,006 worth of shares (23,370 units at $14.72), decreasing direct ownership by 27% to 64,745 units (SEC Form 4)
- AngioDynamics to Participate in Upcoming Investor Conferences
- SVP International Piccinini Laura converted options into 8,047 shares and covered exercise/tax liability with 4,506 shares, increasing direct ownership by 5% to 81,929 units (SEC Form 4) (tax withholding)
- EVP and CFO Trowbridge Stephen A converted options into 16,296 shares and covered exercise/tax liability with 8,319 shares, increasing direct ownership by 3% to 305,796 units (SEC Form 4) (tax withholding)
- President and CEO Clemmer James C converted options into 52,358 shares and covered exercise/tax liability with 26,728 shares, increasing direct ownership by 3% to 862,448 units (SEC Form 4) (for withholding tax)
- SVP Quality and Regulatory Nighan Warren Jr converted options into 5,694 shares and covered exercise/tax liability with 1,671 shares, increasing direct ownership by 5% to 88,115 units (SEC Form 4) to satisfy withholding obligation
- SVP/GM, Vascular Access Campbell Chad Thomas converted options into 6,466 shares and covered exercise/tax liability with 2,330 shares, increasing direct ownership by 4% to 108,676 units (SEC Form 4) to satisfy withholding obligation
- Director Johnson Wesley was granted 11,887 shares, increasing direct ownership by 8% to 155,425 units (SEC Form 4)
- SVP Quality and Regulatory Nighan Warren Jr was granted 17,966 shares, increasing direct ownership by 27% to 84,092 units (SEC Form 4)
- Director Burgess Lorinda was granted 11,887 shares, increasing direct ownership by 22% to 67,144 units (SEC Form 4)
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.